Citi Resets Life Sciences And MedTech Views

Citi has overhauled its view on several major healthcare and life science names, issuing new ratings and target changes across life science tools, diagnostics, and medical technology stocks. The moves follow a turbulent earnings season and rising market volatility, with the VIX recently elevated.

In tools and diagnostics, Citi opened a 90‑day upside catalyst watch on Agilent Technologies, cut its price target on Icon PLC, and named Agilent, Natera and Charles River Laboratories as top picks in their respective sub‑sectors. In MedTech, the bank upgraded Intuitive Surgical to Buy, added a 90‑day catalyst watch on Stryker, and trimmed its target on Abbott while reiterating a Buy rating.

Citi’s catalyst watch on Agilent focuses on the company’s pending $950 million all‑cash acquisition of Biocare Medical, announced March 9, 2026. The deal adds more than 300 specialized antibodies and tissue diagnostic capabilities, enhancing Agilent’s position in an estimated $10 billion pathology market.

The firm expects Agilent’s valuation multiple to rebound once the Biocare transaction closes, which is anticipated by the fourth quarter of Agilent’s fiscal 2026. Agilent is Citi’s top pick among tools companies, with a Buy rating and $185 price target, above the broader consensus target of $163.29.

Agilent shares have fallen 15% year to date to $115.43, well below a 52‑week high of $159.98. However, Q1 fiscal 2026 revenue rose 7% year over year to $1.80 billion, and full‑year revenue guidance was raised to a range of $7.3 billion to $7.5 billion. The CrossLab services unit delivered $758 million of revenue with a 31.6% operating margin.

In contrast, Citi reduced its price target on Icon PLC to $120 from $200 while maintaining a Neutral rating. The change follows Icon’s disclosure in February 2026 that an internal accounting investigation found potential revenue overstatement across fiscal years 2023 through 2025.

Preliminary indications point to less than 2% revenue overstatement per year, but Icon has delayed its Q4 and full‑year 2025 results until on or before April 30, 2026. Citi’s Neutral stance reflects a wait‑and‑see approach until restated financials clarify the impact.

Icon shares have dropped 41% year to date and 41.65% over the past year to $106.62, far below a 52‑week high of $211.00. Quarterly earnings growth has fallen 98.7% year over year on a trailing basis, and the stock now trades below book value with a price‑to‑book ratio of 0.9.

Within diagnostics, Citi named Natera its top pick following a sharp earnings inflection. Natera posted Q4 2025 EPS of $0.36 compared with an estimate of -$0.4998, marking a return to profitability that exceeded expectations. The shares have risen 50% over the past 12 months, despite a 13.16% year‑to‑date pullback to $198.95.

Charles River Laboratories is Citi’s preferred contract research organization. Management is guiding for a return to organic growth in the second half of 2026, and the stock has declined 16.1% year to date to $167.37, below its 200‑day moving average of $172.30. Citi’s stance reflects a view of a business working through a cyclical trough.

In medical technology, Citi upgraded Intuitive Surgical to Buy from Neutral with a $590 price target. The firm argues that the stock’s pullback has outpaced any change in fundamentals, as Intuitive continues to deliver double‑digit growth and earnings leverage.

Intuitive beat EPS and revenue estimates in all four quarters of 2025. Q4 2025 revenue reached $2.87 billion, up 18.76% year over year, with non‑GAAP EPS of $2.53 versus a $2.26 consensus. The da Vinci 5 system saw 303 placements in Q4, up from 174 a year earlier, bringing the installed base to 11,106 systems, a 12% increase.

Shares trade around $485.85, down 14.2% year to date after ending 2025 near a 52‑week high of $603.88. Citi notes that Intuitive trades at roughly 49 times forward earnings and faces tariff headwinds of about 1.2% of revenue in 2026, but continues to project da Vinci procedure growth of 13% to 15%.

Citi maintained its Buy rating on Stryker and added a 90‑day catalyst watch, highlighting consistent double‑digit revenue and earnings growth and early data from the Mako RPS handheld robotic system, which entered limited market release heading into 2026.

Stryker generated $25.12 billion in 2025 revenue, up 11.16%, and expanded adjusted operating margins by at least 100 basis points for a second consecutive year. The stock trades at $358.65, up 2% year to date but down 6.7% over the past week.

For Abbott, Citi lowered its price target to $136 from $140 but kept a Buy rating, characterizing the move as a post‑Q4 adjustment rather than a shift in conviction. Abbott shares are at $110.55, down 11.3% year to date and 18% over the past year.

Q4 revenue for Abbott was $11.46 billion, up 4.42% year over year, with the medical devices segment generating $2.0 billion in continuous glucose monitoring sales, a 15% increase. The company’s pending $21 billion acquisition of Exact Sciences, expected to close in Q2 2026, would add a cancer diagnostics platform.